drugset / Trial / NCT05995392

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392

Phase 0 Unknown 30 enrolled Richard W Yee, MD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the clinical efficacy of topical spironolactone ophthalmic solution, 0.005 mg/cc in subjects with dry eye disease compared to placebo. The hypothesis for this study is that topical spironolactone ophthalmic solution will be beneficial in the management of signs and symptoms of dry eye disease when compared to placebo.

Timeline

Start
2023-08
Primary completion
2024-02
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 0.005 mg/ml Topical

Indications